Services on Demand
- Cited by SciELO
- Access statistics
- Similars in SciELO
Print version ISSN 0042-9686
Bull World Health Organ vol.81 n.5 Genebra Jan. 2003
POLICY AND PRACTICE
Fever and antipyresis
Heinz F. Eichenwald
Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA (email:Heinz.Eichenwald@utsouthwestern.edu)
Whether fever represents a beneficial or harmful response to infection has been debated for hundreds of years. The issue is clouded by a common misunderstanding that fever is the reason an individual with infection feels ill: often once the elevated body temperature abates, the patient feels better. It is assumed therefore that reducing the fever would improve the patient's condition and shorten their illness. From there, it is only a short step to conceive of the fever as the illness itself.
Although this logical fallacy remains attractive to medical personnel and patients, what evidence exists that fever is harmful or beneficial to the course of an infectious illness? At first glance, studies to answer the question seem simple to perform. Unfortunately, however, to investigate the problem directly is virtually impossible, because every method available to reduce fever has secondary metabolic consequences: antipyretics affect the body in many ways, and even physical methods such as sponging with cold water result in a wide range of responses, including shivering and stimulation of the adrenalcortical axis. We thus must seek other lines of evidence ranging from teleology and comparative zoology through detailed clinical observation of defined cases to molecular biology.
Perhaps the most powerful arguments to support a beneficial effect of fever on infection come from teleology and genetics. Fever is established as a phylogenetically ancient host response that is conserved highly in all mammals (1). That fever, despite high metabolic and nutritional costs, is conserved so highly argues forcefully for its evolutionary value, as does the endogenous nature of its mechanism, which requires a complex series of steps and interactions. Recent work on the biology of cytokines has enabled the effects of individual components of this response all of which are beneficial to the host to be examined. It is reasonable to argue on the basis on the many similarities in the febrile response and its mechanism among different vertebral classes, that fever is an adaptive benefit to the host despite the fact that it is an energy-expensive phenomenon. Our inability to demonstrate directly the beneficial effects of fever in the intact vertebral host because of the diverse metabolic effects of antipyresis means that this evolutionary evidence is probably the best we have.
Some support for fever comes from comparative biology. Cold-blooded animals such as lizards lack a mechanism to produce fever when they become infected. A "heat-seeking" instinct has been described in these creatures, however; this allows them to raise their body temperature by external means: the animals find the warmest spot in the environment and remain there while their body temperature increases in response to the external stimulus. The survival value of such behaviour has been shown clearly in the laboratory.
A question often raised about the evolutionary argument is why fever would be beneficial in mild to moderately severe infections but demonstrably deleterious in fulminant disease (2). Such a difference can be explained by the fact that evolution has no interest in the preservation of the individual, only in preserving the species: recovery of many individuals with mild to moderately severe infections is far more important than the survival of the occasional case of fulminant illness.
As Russell et al. point out, it has proved difficult to show an unequivocal effect from reducing fever as part of the treatment of infection. As mentioned, to undertake such studies is a daunting task because a beneficial effect predictably would be found primarily in mild to moderately severe disease, end-points are impossible to select. Obviously the duration of fever cannot be one endpoint, but what other sign or symptom can be objectively and quantitatively measured in a reproducible manner? Hundreds and probably thousands of patients would have to be enrolled in double- blind, placebo-controlled studies and followed in exquisite detail. This is why so little clinical data are available, and it seems unlikely that more will be obtained. The information summarized by Russell et al., however, does seem to support the conclusion that reducing fever in mild infection can adversely influence the course of at least some illnesses.
On the other hand, good evidence supports the view that the high fevers encountered in septic states are deleterious to the host and that their suppression is helpful in assuring survival (2). As pointed out earlier, these instances are comparatively rare, and from an evolutionary perspective all of the affected individuals would have died.
In addition to the probability that antipyretics may prolong the course of mild to moderate infectious illnesses, what other deleterious effects might they have? Russell et al. point out that little is known about the pharmacokinetics of these drugs in poorly or malnourished children. Even in developed countries, all available methods of antipyresis must be treated with respect. Warning labels became required for paracetamol recently and for aspirin in the more distant past. In addition to acute poisoning, the former has been implicated in the development of chronic renal disease, and perhaps liver failure, when repeatedly administered over prolonged periods of time (3). Perhaps more important is the fact that antipyretics mask symptoms or signs; children with pneumonia, for example, may not receive a proper diagnosis because their respiratory rate decreases (4) or because, when the body temperature starts to fall, the child may be considered to be on the way to recovery and thus needing no further observation. Finally, of course, the costs may consume a significant amount of resources that, in developing countries, could be better devoted to specific diagnosis and therapy.
Other potential benefits of reducing fever are sometimes cited to justify the use of antipyresis. A common assumption is that these drugs make patients feel better, but no clear evidence shows that this is so. Parents and physicians consistently cannot distinguish between the effects of placebo and paracetamol in most circumstances (5). Perhaps the exceptions are conditions accompanied by pain, for which the analgesic effects of the medication provide the benefit. When fevers rise above 39.5 oC, a reduction in body temperature is sometimes accompanied by an improvement in subjective symptoms, but this is inconstant, with young children seeming to benefit more than older children (6).
The major problem when evaluating the subjective effects of antipyretics is that they have an enormous placebo value as various studies have shown (5, 6). Despite the firm belief in the effects of antipyretics, children do not feel any better, eat better, or become more active after their use than they do after they receive placebo. The argument that the use of antipyretics reduces the occurrence of febrile seizures also is not based on evidence: no studies have shown this to be true. Even in children with previous febrile seizures, the use of antipyretics has not been helpful (7). Some physicians believe that the response to antipyretics can be used to differentiate between bacterial and viral infections, with the latter responding more completely and promptly. Numerous studies have shown this to be a fallacy (8, 9).
In summary, what does the evidence seem to indicate? Fever represents a universal, ancient, and usually beneficial response to infection, and its suppression under most circumstances has few, if any, demonstrable benefits. On the other hand, some harmful effects have been shown to occur as a result of suppressing fever: in most individuals, these are slight, but when translated to millions of people, they may result in an increase in morbidity and perhaps the occurrence of occasional mortality. It is clear, therefore, that widespread use of antipyretics should not be encouraged either in developing countries or in industrial societies. Unfortunately though, just as fever represents an ancient biological response, an emotional effect is embedded deeply. Through the ages, parents have seen that when fever begins to diminish and disappears, the child feels better and recovers from the illness whatever it was. Thus, the fever has become synonymous with the illness. This flaw in logic has persisted in parents' and physicians' minds, and they are seduced by the thought that if they "make the fever go away, the patient will be well." No amount of scientific discourse will change this attitude, and antipyresis will continue to be used in children with low-grade fevers, or even no fevers, in the home as well as the hospital. A reasonable evidence-based approach is to discourage the use of antipyretics in fevers <39 oC, reserving them for patients with higher temperatures.
Conflicts of interest: none declared.
1. Kluger MJ. Phylogeny of fever. Federation Proceedings 1979;38:30-4.
2. Mackowiak PA. Fever: blessing or curse? A unifying hypothesis. Annals of Internal Medicine 1994;120:1037-40.
3. Maher JF. Analgesic nephropathy. American Journal of Medicine 1984;76: 345-8.
4. O'Dempsey TJ, Laurence BE, McArdle TF, Todd JE, Lamont AC, Greenwood BM. The effect of temperature reduction on respiratory rate in febrile illnesses. Archives of Diseases in Childhood 1993;68:492-5.
5. Kramer MS, Naimark LE, Roberts-Brauer R, McDougall A, Leduc DG. Risks and benefits of paracetamol antipyresis in young children with fever of presumed viral origin. Lancet 1991;337:591-4.
6. Bonadio WA, Bellomo T, Brady W, Smith D. Correlating changes in body temperature with infectious outcome in febrile children who receive acetaminophen. Clinical Pediatrics 1993;32:343-6.
7. Schnaiderman D, Lahat E, Sheefer T, Aladjem M. Antipyretic effectiveness of acetaminophen in febrile seizures: ongoing prophylaxis versus sporadic use. European Journal of Pediatrics 1993;152:747-9.
8. Weisse ME, Miller G, Brien JH. Fever response to acetaminophen in viral vs. bacterial infection. Pediatric Infectious Diseases Journal 1987;6:1091-4.
9. Baker MD, Fosarelli PD, Carpenter RO. Childhood fever: a correlation of diagnosis with temperature response to acetaminophen. Pediatrics 1987;80:315-8.